Robert J. Bitterman - 16 Nov 2022 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Role: Interim Executive Chairman, Director
Signature: Caitlin Kontulis, attorney-in-fact
Issuer symbol: PHIO
Transactions as of: 16 Nov 2022
Net transactions value: +$1,750
Form type: 4
Filing time: 16 Nov 2022, 16:06:34 UTC
Previous filing: 03 Oct 2022
Next filing: 29 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PHIO	Series D Preferred Stock, $0.0001 par value	Purchase	$1,750	+1		$1750.00	1	16 Nov 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The outstanding share of Series D Preferred Stock shall be redeemed in whole, but not in part, at any time: (i) if such redemption is approved by the Board of Directors in its sole discretion or (ii) automatically and effective upon the approval of an amendment to the Certificate of Incorporation to implement a reverse stock split. Upon redemption, the share of Series D Preferred Stock will receive consideration of $1,750.00 in cash.

Content

The outstanding share of Series D Preferred Stock shall be redeemed in whole, but not in part, at any time: (i) if such redemption is approved by the Board of Directors in its sole discretion or (ii) automatically and effective upon the approval of an amendment to the Certificate of Incorporation to implement a reverse stock split. Upon redemption, the share of Series D Preferred Stock will receive consideration of $1,750.00 in cash.